Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

A high-throughput screen to study the role of stem cells in hemangioma tumor formation

ABSTRACT: To further the development of gene expression signatures for infantile hemangioma (IH) cells, gene expression analysis was performed of different human cell samples using Agilent whole human genome oligo microarrays. The purpose of the experiments are: a) to identify the intrinsic differences between HemSc and HemDerivatives and compare HemSc and HemDerivatives genetically; b) analyze the "stemness" genes, paracrine/endocrine associated genes ("angiocrine"), and genes that regulate development, vasculogenesis and immunity; c) identify involvement of the signaling pathways at various stages of differentiation; and d) provide new perspectives on the failure of anti-vasculogenic inhibitors currently in use.

ORGANISM(S): Homo sapiens

PROVIDER: GSE34989 | GEO | 2014/05/31

SECONDARY ACCESSION(S): PRJNA151091

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

An endothelial SOX18-mevalonate pathway axis enables repurposing of statins for infantile hemangioma [Day 4]

Project description:Infantile hemangioma (IH) is the most common tumor in children and a paradigm for pathological vasculogenesis, angiogenesis and regression. Propranolol is the mainstay of treatment for IH. It inhibits hemangioma vessel formation via a β-adrenergic receptor independent effect of its R(+) enantiomer on the endothelial specific transcription factor sex-determining region Y (SRY) box transcription factor 18 (SOX18). Transcriptomic profiling of patient-derived hemangioma stem cells uncovered the mevalonate pathway (MVP) as a target of R(+) propranolol. Loss of SOX18 function confirmed R(+) propranolol mode of action on the MVP. Functional validation in preclinical IH models revealed that statins - targeting the MVP - are potent inhibitors of hemangioma vessel formation. We propose a novel SOX18-MVP-axis as a central regulator of IH pathogenesis and suggest statin repurposing to treat IH.

2025-03-07 | GSE275019 | GEO

An endothelial SOX18-mevalonate pathway axis enables repurposing of statins for infantile hemangioma [Day 6]

2025-03-07 | GSE274946 | GEO

microRNA analysis of infantile hemangioma, lymphatic malformation, and skin

Project description:Surgical specimens from children with infantile hemangioma or lymphatic malformations, as well as healthy appearing adjacent skin, were analyzed by microarray analysis of microRNA expression. Unsupervised hierarchical clustering was performed to identify microRNAs that were differentially expressed in IH compared to lymphatic malformations and skin 19 patients who underwent surgical excision of either a lymphatic malformation or infantile hemangioma were used in the study. 5 patients have multiple samples on the array and these duplicates are from different regions of the excised tissue or separate lesions as indicated. Tissue was snap frozen in liquid nitrogen and used for RNA extraction

2015-05-22 | E-GEOD-69136 | biostudies-arrayexpress

Transcription factor KLF2 regulates cell fate decision of stem cells in infantile hemangioma

Project description:As the most common vascular tumor during infancy, infantile hemangioma (IH) is clinically featured by a rapid proliferation phase of disorganized blood vessels and a subsequent spontaneous involution phase. Infantile hemangioma arises from a unique type of multipotent stem cells called hemangioma stem cells (HemSCs), which could differentiate into endothelial cells, pericytes and adipocytes in IH. However, the underlying mechanisms that regulate the cell fate determination of HemSCs are not well elucidated. Here, we identified KLF2 as a candidate transcription factor involved in the control of HemSCs differentiation. KLF2 was expressed in endothelial cells in proliferating IH and its expression diminished in adipocytes in involuting IH. KLF2 regualtes the proliferation, apopotosis and cell cycle progression in HemSCs. Moreover, KLF2 is a critical regulator in HemSCs that control their differentiation direction between endothelial cells and adipocytes. Knockdown of KLF2 inhibited the formation of blood vessels in vivo while accelerated the progress of adipogenesis. RNA-seq analysis suggested an induction of pro-adipogenic transcriptome in HemSCs upon KLF2 knockdown. Our data showed that KLF2 exhibited pleiotropic effects in regulating the biological behaviours of HemSCs, and was involved in the progression and involution of IH via determining the cell fate of HemSCs.

2024-08-01 | GSE239352 | GEO

microRNA analysis of infantile hemangioma, lymphatic malformation, and skin

2016-06-09 | GSE69136 | GEO

lncRNA expression profile identified by microarray in infantile hemangioma

Project description:Infantile hemangioma (IH) was one of the most common vascular tumors during childhood. Long non coding RNAs (lncRNAs) play great roles in angiogenesis; the involvement of lncRNAs in hemangioma remains unknown. We aim to investigate the differential expression of lncRNA between hemangioma and the adjacent normal tissues, with a view to studying the biological function of lncRNAs and their involvement in the pathogenesis of hemangioma. The differential lncRNAs expression profiles of hemangioma were established by lncRNA microarray. Bioinformatic analyses were applied for further study of these differentially expressed lncRNAs. A total of 2116 differentially expressed lncRNAs were identified, among these lncRNAs, 1259 were up-regulated and 857 were down-regulated more than two-fold.

2016-03-03 | GSE78811 | GEO

OTUB1 catalytic-independently deubiquitinates TGFBI and mediates the angiogenesis in infantile hemangioma by regulating glycolysis

Project description:To investigate the role of Ubiquitination in the progression of infantile hemangioma. And to investigate the role of OTUB1 in infantile hemangioma

2023-03-14 | GSE225591 | GEO

Critical role of Aquaporin-1 and telocytes in infantile hemangioma response to propranolol beta-blockade

Project description:Propranolol, a non-selective β-adrenergic receptor (ADRB) antagonist, is the first-line therapy for severe infantile hemangiomas (IH). Since the incidental discovery of propranolol efficacy in IH, preclinical and clinical investigations have shown evidence of adjuvant propranolol response in some malignant tumors. However, the mechanism for propranolol antitumor effect is still largely unknown, owing to the absence of a tumor model responsive to propranolol at non-toxic concentrations. Immunodeficient mice engrafted with different human tumor cell lines were treated with anti-VEGF bevacizumab, to create a model sensitive to propranolol. Proteomics analysis was used to reveal propranolol-mediated protein alteration correlating with tumor growth inhibition and Aquaporin-1 (AQP1), a water channel modulated in tumor cell migration and invasion, was identified. IH tissues and cells were then functionally investigated. Our functional protein association networks analysis and knockdown of ADRB2 and AQP1 indicated that propranolol treatment and AQP1 downregulation trigger the same pathway, suggesting that AQP1 is a major driver of betablockers antitumor response. Examining AQP1 in human hemangioma samples, we found it exclusively in a perivascular layer, so far unrecognized in IH, made of telocytes (TC). Functional in vitro studies showed that AQP1-positive telocytes play a critical role in IH response to propranolol and that modulation of AQP1 in IH-TC by propranolol or shAQP1 decreases capillary-like tube formation in a Matrigel based angiogenesis assay. We conclude that IH sensitivity to propranolol may rely at least in part to a cross talk between lesional vascular cells and stromal telocytes.

2021-01-25 | PXD021457 | Pride

Genome-wide transcriptome comparison between primary cultures of human dermal microvascular endothelial cells and infantile hemangioma endothelial cells

Project description:Whole transcriptome comparisons of proliferating pure cultures of neonatal dermal microvacsular endothelial cells to infantile hemangioma endothelial cells. The total RNA was obtained from human dermal microvascular endothelial cells and infantile hemangioma endothelial cells. Illumina microarrays were performed to determine the whole genome expression differences between the cell lines.

2013-06-01 | E-GEOD-43742 | biostudies-arrayexpress

Exploring gene expression signatures of itraconazole for infantile hemangioma endothelial cell in vitro

Project description:In order to understand the mechanisms underlying the effects of itraconazole in infantile hemangioma endothelial cells, we further explored the potential targeting genes of itraconazole in infantile hemangioma endothelial cells in vitro by using a genome-wide gene expression array. In total 172 mRNAs were up-regulated (fold change > 2) and 819 mRNAs were down-regulated (fold change > 2) upon itraconazole treatment in infantile hemangioma endothelial cells. The top signaling pathway closely related to differentially expressed genes upon itraconazole treatment is the cytokine and cytokine receptor pathway. Within this pathway, the mRNA expression of PDGF-D, an important growth factor belonging to the PDGF family, was the most significantly reduced (30 folds) among 991 differentially expressed genes after itraconazole treatment. qRT-PCR and western blotting confirmed the inhibitory effects on PDGF-D levels.

2021-11-29 | GSE123108 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data